Pharmaceuticals

Group B Streptococcus Infection Treatment Market Outlook: Growth and Forecast Highlights 2030

March 4, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the group b streptococcus infection treatment market from 2026–2035 with trusted insights from The Business Research Company

What level of growth is expected in the Group B Streptococcus Infection Treatment Market between 2026 and 2030?

The group b streptococcus infection treatment market has experienced significant growth in recent years. It is anticipated to expand from $1.26 billion in 2025 to $1.36 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.3%. The historical surge in this market can be ascribed to an elevated awareness concerning neonatal infections, the expansion of prenatal care initiatives, the widespread adoption of beta-lactam antibiotics, an increase in hospital-based screening protocols, and the availability of microbiological testing services.

The market for group b streptococcus infection treatment is anticipated to experience robust expansion over the coming years, reaching a valuation of $1.89 billion by 2030, driven by a compound annual growth rate (CAGR) of 8.6%. This projected growth during the forecast period is attributable to several factors, including the increasing development of GBS vaccines, a rising embrace of point-of-care diagnostics, a heightened focus on managing antimicrobial resistance, the expansion of molecular testing infrastructure, and an increased emphasis on preventive maternal healthcare. Key trends characterizing the forecast period encompass a growing adoption of rapid molecular diagnostic testing, an increasing focus on prenatal GBS screening programs, a wider application of antibiotic stewardship protocols, the expansion of pipeline therapies aimed at GBS prevention, and improved monitoring of maternal and neonatal outcomes.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33144&type=smp

Which Drivers Are Expected To Impact The Group B Streptococcus Infection Treatment Market During The Forecast Period?

The increasing financial outlay on healthcare is anticipated to foster the expansion of the group B streptococcus infection treatment market in the future. This expenditure encompasses all monetary resources allocated for medical services, preventative measures, pharmaceutical products, healthcare infrastructure, and associated activities aimed at sustaining or enhancing public health. The upward trend in healthcare spending is driven by the growing incidence of both chronic and infectious illnesses, which in turn generates a persistent need for prolonged treatment, sophisticated therapies, and ongoing medical attention. An increase in healthcare spending bolsters the management of group B Streptococcus infections through enhanced investment in prenatal screening programs, clinical facilities, and vaccine development, collectively leading to better early detection, prevention, and successful handling of GBS infections in both mothers and their infants. As an illustration, in April 2025, the Office for National Statistics, a government body in the UK, reported that total healthcare spending saw a 6.5% increase from 2023 to 2024, indicating a quicker rate of growth compared to the 6.3% rise observed in 2023. Consequently, the escalating healthcare expenditure is propelling the expansion of the group B streptococcus infection treatment market.

Which Segments Are Driving Activity In The Group B Streptococcus Infection Treatment Market?

The group b streptococcus infection treatment market covered in this report is segmented –

1) By Treatment Type: Antibiotic Therapy; Intravenous Immunoglobulin (IVIG); Experimental Therapies

2) By Drug Class: Beta-Lactam Antibiotic; Clindamycin And Alternatives; Pipeline Therapies

3) By Route of Administration: Oral Administration; Intravenous Administration; Topical Application

4) By Patient Type: Newborns; Pregnant Women; Immunocompromised Patients; Elderly Population

5) By End User: Hospitals; Clinics; Research Institutions; Home Care Settings

Subsegments:

1) By Antibiotic Therapy: Penicillin Based Antibiotics; Cephalosporin Antibiotics; Macrolide Antibiotics; Aminoglycoside Antibiotics

2) By Intravenous Immunoglobulin (IVIG): Standard Polyclonal Immunoglobulin; High Dose Immunoglobulin Therapy; Adjunctive Immunoglobulin Therapy

3) By Experimental Therapies: Vaccine Based Therapies; Monoclonal Antibody Therapies; Bacteriophage Therapies; Immunomodulatory Therapies

What Industry Trends Are Transforming The Group B Streptococcus Infection Treatment Market?

Leading companies in the group B streptococcus infection treatment market are concentrating on developing innovative products, such as polysaccharide conjugate vaccines, to reduce asymptomatic bacterial carriage. Polysaccharide conjugate vaccines are immunizations where bacterial surface sugars are chemically linked to a carrier protein, aiming to enhance immune recognition and generate a strong, long-lasting protective response, particularly in infants and young children. For instance, in September 2023, Omniose, a US-based biotechnology company, announced a grant award of up to $3.0 million from the National Institute of Allergy and Infectious Diseases at the U.S. National Institutes of Health to support the development of a Group B Streptococcus (GBS) vaccine. The vaccine’s distinctive feature is its goal to achieve high efficacy through a highly simplified manufacturing approach. Omniose’s platform utilizes synthetic biology and a one-step enzymatic process within a single re-engineered E. coli cell to produce GBS polysaccharide conjugate vaccines, thus eliminating conventional chemical conjugation steps. This process preserves 100% of sialic acid residues on each capsular polysaccharide, a factor demonstrated to be critical for inducing strong functional antibody responses against specific GBS serotypes.

Which Major Industry Participants Are Leading The Group B Streptococcus Infection Treatment Market Growth?

Major companies operating in the group b streptococcus infection treatment market are Merck & Co. Inc., Pfizer Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Biological E. Limited, Serum Institute of India Pvt. Ltd., Walvax Biotechnology Co. Ltd., Vaxcyte Inc., Bharat Biotech International Limited, Clover Biopharmaceuticals Ltd., Biovac Institute (Pty) Ltd., Inventprise Inc., BioNet Asia Co. Ltd., GeneOne Life Science Inc., Alopexx Enterprises LLC, Wellstat Vaccines LLC, MinervaX ApS, and ShanghAI Zerun Biotechnology Co. Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/group-b-streptococcus-infection-treatment-market-report

Which Region Is Expected To Experience The Fastest Growth In The Group B Streptococcus Infection Treatment Market?

North America was the largest region in the group B streptococcus infection treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the group b streptococcus infection treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Group B Streptococcus Infection Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=33144&type=smp

Browse Through More Reports Similar to the Global Group B Streptococcus Infection Treatment Market 2026, By The Business Research Company

Strep Throat Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/strep-throat-treatment-global-market-report

Antibacterial Products Market Report 2026

https://www.thebusinessresearchcompany.com/report/antibacterial-products-global-market-report

Hospital Acquired Infection Control Market Report 2026

https://www.thebusinessresearchcompany.com/report/hospital-acquired-infection-control-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795